yeah finally, why were we waiting so long?????
Must be nice, they used my 150k plus all others $$$$ that did not tender for a month. How the hell do we get in on that game? LOL!
Going toadd to my RMTI position, looks like another TSRX brewing.
I did not tender my shares. I called Eileen McIntyre-invest-relations @ Cubist This morning 10/08/13. She told me to talk to my broker #$%$ should be disbursed by computershares company. I called TDAmeritrade and they said that I should expect to see $$ tomorrow.
I did not tender, but wish I did, I would have been nice to build a bigger raft in the RMTI pond, hoping for a little pull back, before KABOOM
One day you will wake up, check your account, and wallah, the money will be there, gauranteed....no worries...
I did not tender.... Anyone know what happens to those like me??? Will Cubist be in touch - to tender?? Any idea when???? Thanks! Took the advice from someone on this board to look at TTPH... THANK YOU!
I'll drink to that. Cheers.
btw, have reinvested some TSRX $ and have now small rafts at RMTI, HALO and CLDX.
Hope to see some of you around from time to time.
FDA approval for Focalin XR expected for this Quarter...GL
This Low float Stock awaiting 8 FDA approvals and has another 2 Potential Blockbusters ready for Phase 3
Foclian XR alone which is Partnered with Par Pharma will drive IPCI deep into Profitability quickly after Market Launch .There is NO generic version of Focalin XR available on the Market , IPCI & Par will be the first here and its normal that the first generic takes 30%-40% of market share quickly after launch .
5-6 FDA approvals expcted within 12 months .This Gem has everything to move into Double Digits the Market Cap of $40 Million is a Big Joke .
Market Cap:$ 39 M
Cash : $3 M
Shares Out: 21 Mil..(10 Mil Shares held by Insiders/Institutions)
Low Float: 11 M
8 Generic Drug Applications Filed with the FDA
We currently have eight Abbreviated New Drug Applications awaiting FDA approval. These include generics of Focalin XR® Effexor XR®, Protonix ®' Glucophage ® XR,Seroquel XR®, Lamictaf® XR Keppra XR® and Pristiq® .Together, these products represent approximately $4.78 of branded and generic sales.
Our lead product, a generic version of Focal in XR®, is partnered with Par Pharmaceuticals Inc., a top ten U.S.pharmaceutical company.As a result of a settlement with the innovator company, we expect to marketing of our generic versions ofFocalin XR® upon approval. We have a ten year profit-sharing agreement with Par for the sale of a generic version of Focal in XR® in the U.S.,which commences with the commercial launch of the product by Par .